Abstract:Safely and efficiently controlling gene expression is a long-standing goal of biomedical research, and the recently discovered bacterial CRISPR/Cas system can be harnessed to create powerful tools for epigenetic editing. Current state-of-the-art systems consist of a deactivated-Cas9 nuclease (dCas9) fused to epigenetic effector motifs/domains, along with a guide RNA (gRNA) which defines the genomic target. Such systems have been used to safely and effectively silence or activate a specific gene target under a variety of circumstances. Adeno-associated virus (AAV) vectors are the therapeutic platform of choice for delivery of genetic cargoes; nevertheless, their small packaging capacity is not suitable for the delivery of large constructs, including most CRISPR/dCas9-effector systems. To circumvent this, many AAV-based CRISPR/Cas tools are delivered separately from two viral cassettes. However, this approach requires higher viral payloads and usually is less efficient. Here we develop a compact dCas9-based repressor system packaged within a single, optimized AAV vector. The system uses a smaller dCas9 variant derived from Staphylococcus aureus (Sa). A novel repressor was engineered by fusing the small transcription repression domain (TRD) from MeCP2 with the KRAB repression domain. The final dSaCas9-KRAB-MeCP2(TRD) construct can be efficiently packaged, along with its associated gRNA, into AAV particles. Using reporter assays, we demonstrate that the platform is capable of robustly and sustainably repressing the expression of multiple genes-of-interest, both in vitro and in vivo. Most relevantly, we successfully silenced APOE, the primary genetic risk factor for late onset Alzheimer disease (LOAD). This new platform will broaden the CRISPR/dCas9 toolset available for transcriptional manipulation of gene expression in research and therapeutic settings.

A Novel CRISPR Interference Effector Enabling Functional Gene Characterization with Synthetic Guide RNAs

Programmable DNA Repair with CRISPRa/i Enhanced Homology-Directed Repair Efficiency with a Single Cas9

Higher-order combinatorial chromatin perturbations by engineered CRISPR-Cas12a for functional genomics

Engineered CRISPR-Cas12a for higher-order combinatorial chromatin perturbations

Supramolecular Nanosubstrate‐Mediated Delivery for CRISPR/Cas9 Gene Disruption and Deletion

Disrupting Protein Expression with Double-Clicked sgRNA-Cas9 Complexes: A Modular Approach to CRISPR Gene Editing

A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes in vitro and in vivo

Non-Viral CRISPR/Cas Gene Editing in Vitro and in Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 Mrna and Sgrna.

A Tet-Inducible CRISPR Platform for High-Fidelity Editing of Human Pluripotent Stem Cells

Enhanced in vivo gene knockout with undetectable off-targets using multiplexed Cas12a sgRNAs

Temporal Restriction of Cas9 Expression Improves CRISPR-Mediated Deletion Efficacy and Fidelity

Quantitative CRISPR interference screens in yeast identify chemical-genetic interactions and new rules for guide RNA design

Functional Non-Homologous End Joining Patterns Triggered by CRISPR/Cas9 in Human Cells.

Identification and Optimization of Novel Small-Molecule Cas9 Inhibitors by Cell-Based High-Throughput Screening.

A Targeted and Tuneable DNA Damage Tool Using CRISPR/Cas9

Expression of Single mRNA Constructs Encoding Both CRISPR-Cas9 Protein and Guide RNAs for Future Gene Therapy Applications

A novel sgRNA selection system for CRISPR-Cas9 in mammalian cells

Arrayed CRISPR libraries for the genome-wide activation, deletion and silencing of human protein-coding genes

Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening

All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders

Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex